EE03090B1 - Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks - Google Patents

Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks

Info

Publication number
EE03090B1
EE03090B1 EE9400269A EE9400269A EE03090B1 EE 03090 B1 EE03090 B1 EE 03090B1 EE 9400269 A EE9400269 A EE 9400269A EE 9400269 A EE9400269 A EE 9400269A EE 03090 B1 EE03090 B1 EE 03090B1
Authority
EE
Estonia
Prior art keywords
quinoline
diabetes
preparation
treatment
composition
Prior art date
Application number
EE9400269A
Other languages
English (en)
Inventor
Slavin Shimon
Weiss Lola
Gross David
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of EE03090B1 publication Critical patent/EE03090B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9400269A 1992-04-06 1994-11-17 Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks EE03090B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201076A SE9201076L (sv) 1992-04-06 1992-04-06 Användningen av gamla läkemedel för behandling av diabetes

Publications (1)

Publication Number Publication Date
EE03090B1 true EE03090B1 (et) 1998-06-15

Family

ID=20385863

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400269A EE03090B1 (et) 1992-04-06 1994-11-17 Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks

Country Status (16)

Country Link
US (1) US5594005A (et)
EP (1) EP0634931A1 (et)
JP (1) JPH07506568A (et)
KR (1) KR950700738A (et)
CN (1) CN1081671A (et)
AU (1) AU667362B2 (et)
CA (1) CA2131831C (et)
EE (1) EE03090B1 (et)
HU (1) HUT69710A (et)
IL (1) IL105285A0 (et)
NO (1) NO943723D0 (et)
NZ (1) NZ251494A (et)
PH (1) PH30820A (et)
SE (1) SE9201076L (et)
WO (1) WO1993019756A1 (et)
ZA (1) ZA932450B (et)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
FR2827600A1 (fr) * 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8653143B2 (en) * 2008-10-09 2014-02-18 Newtree Co., Ltd. Use of panduratin derivative or Boesenbergia pandurata extract
CN103153959A (zh) 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use

Also Published As

Publication number Publication date
CN1081671A (zh) 1994-02-09
NZ251494A (en) 1997-07-27
KR950700738A (ko) 1995-02-20
NO943723L (no) 1994-10-05
CA2131831C (en) 1999-03-09
PH30820A (en) 1997-10-17
IL105285A0 (en) 1993-08-18
SE9201076D0 (sv) 1992-04-06
CA2131831A1 (en) 1993-10-14
EP0634931A1 (en) 1995-01-25
AU3913193A (en) 1993-11-08
JPH07506568A (ja) 1995-07-20
ZA932450B (en) 1993-10-20
WO1993019756A1 (en) 1993-10-14
AU667362B2 (en) 1996-03-21
HU9402854D0 (en) 1995-01-30
NO943723D0 (no) 1994-10-05
SE9201076L (sv) 1993-10-07
US5594005A (en) 1997-01-14
HUT69710A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
FI953180A0 (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
NO930543D0 (no) Doseringsform
DE69228828D1 (de) Stabilisierte parathormonzusammensetzung
DK19893A (da) Praeparat til nasal behandling
DK90089D0 (da) Hudbehandlingspraeparat
EE9400257A (et) Kinoliin-3-karboksamiidi ühendi kasutamine ravimkompositsiooni valmistamiseks
EE03090B1 (et) Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks
AU8225391A (en) The use of inositolmonophosphate for the preparing of a medicament effective as a neuropeptide gamma-antagonist
FI935654A (fi) Kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
DE69323607T2 (de) Flüssige korrekturzusammensetzung
KR930702465A (ko) 카르복시에스테르 복합체를 함유하는 액체 조성물
EP0459660A3 (en) Halopropargyl compounds and the use thereof as microbicides
DK137191A (da) Insulinpraeparat
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
FI934387A0 (fi) 3-substituerade 2-oxi-indol-1-karboxiamid omfattande farmaceutiska kompositioner
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
DE69130639D1 (de) Einzel-flüssigkeit zusammensetzung
KR920700539A (ko) 해중 오염방지 처리 조성물
PH23048A (en) New halocyclopropyl compounds and their use as herbicides
FI894208A (fi) Sorafeeniyhdisteet mikrobisideinä
KR890701106A (ko) 과지혈증의 치료를 위한 옥소퀴나졸린 유도체의 용도
IT1224244B (it) Composizione farmaceutica anoressizzante comprendente 5-idrossitrpofano
SE9200780D0 (sv) Composition for therapeutic use
BR9304388A (pt) Composição terapêutica de uso nasal
GB9022298D0 (en) Treatment composition